Preclinical Research
Preclinical research is conducted in cell cultures or animal models before any human trials. The majority of published peptide data is preclinical and must be interpreted with caution when extrapolating to humans.
Overview
Preclinical research encompasses both in vitro (cell/tissue culture) and in vivo (animal) studies. It is the essential first step in evaluating whether a compound has biological activity and what its potential safety profile might be. Rodent models (mice and rats) are the most common preclinical species; their physiology shares many features with humans but also differs in important ways, including drug metabolism rates, receptor pharmacology, and disease models. The translation rate from positive preclinical findings to successful human trials is historically low — many compounds that show dramatic effects in animal models do not replicate in human studies. This gap underscores the importance of not drawing clinical conclusions from preclinical data alone.
Related Terms
Frequently asked questions
Why is most peptide research preclinical?+
Running clinical trials is expensive, time-consuming, and requires regulatory approval. Most research peptides lack commercial backing for human trials, so their published evidence base is primarily animal studies.
How reliable is animal research for predicting human effects?+
Rodent studies provide important mechanistic insights but frequently do not translate directly to humans. Differences in receptor pharmacology, drug metabolism, and disease biology all affect translatability.
What species are most commonly used in peptide preclinical research?+
Rats and mice dominate peptide preclinical research due to their low cost, short generation times, and well-characterized physiology. BPC-157 studies, for example, are predominantly conducted in rats.